Literature DB >> 31976548

Tetramethylpyrazine: A promising drug for the treatment of pulmonary hypertension.

Yuqin Chen1, Wenju Lu1, Kai Yang1, Xin Duan2, Mengxi Li1, Xiuqing Chen1, Jie Zhang1, Meidan Kuang1, Shiyun Liu1, Xiongting Wu1, Guofa Zou1, Chunli Liu1, Cheng Hong1, Wenjun He1, Jing Liao1, Chi Hou3, Zhe Zhang1, Qiuyu Zheng1, Jiyuan Chen1, Nuofu Zhang1, Haiyang Tang1,4, Rebecca R Vanderpool4, Ankit A Desai4, Franz Rischard4, Stephen M Black4, Joe G N Garcia4, Ayako Makino5, Jason X-J Yuan5, Nanshan Zhong1, Jian Wang1,6,5.   

Abstract

BACKGROUND AND
PURPOSE: Tetramethylpyrazine (TMP) was originally isolated from the traditional Chinese herb ligusticum and the fermented Japanese food natto and has since been synthesized. TMP has a long history of beneficial effects in the treatment of many cardiovascular diseases. Here we have evaluated the therapeutic effects of TMP on pulmonary hypertension (PH) in animal models and in patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH). EXPERIMENTAL APPROACH: Three well-defined models of PH -chronic hypoxia (10% O2 )-induced PH (HPH), monocrotaline-induced PH (MCT-PH) and Sugen 5416/hypoxia-induced PH (SuHx-PH) - were used in Sprague-Dawley rats, and assessed by echocardiography, along with haemodynamic and histological techniques. Primary cultures of rat distal pulmonary arterial smooth muscle cells (PASMCs) were used to study intracellular calcium levels. Western blots and RT-qPCR assays were also used. In the clinical cohort, patients with PAH or CTEPH were recruited. The effects of TMP were evaluated in all systems. KEY
RESULTS: TMP (100 mg·kg-1 ·day-1 ) prevented rats from developing experimental PH and ameliorated three models of established PH: HPH, MCT-PH and SuHx-PH. The therapeutic effects of TMP were accompanied by inhibition of intracellular calcium homeostasis in PASMCs. In a small cohort of patients with PAH or CTEPH, oral administration of TMP (100 mg, t.i.d. for 16 weeks) increased the 6-min walk distance and improved the 1-min heart rate recovery. CONCLUSION AND IMPLICATIONS: Our results suggest that TMP is a novel and inexpensive medication for treatment of PH. Clinical trial is registered with www.chictr.org.cn (ChiCTR-IPR-14005379).
© 2020 The British Pharmacological Society.

Entities:  

Year:  2020        PMID: 31976548      PMCID: PMC7236078          DOI: 10.1111/bph.15000

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  64 in total

Review 1.  Capacitative calcium entry: a central role in hypoxic pulmonary vasoconstriction?

Authors:  Jeremy P T Ward; Tom P Robertson; Philip I Aaronson
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-07       Impact factor: 5.464

2.  Ligustrazine-induced endothelium-dependent relaxation in pulmonary arteries via an NO-mediated and exogenous L-arginine-dependent mechanism.

Authors:  W Peng; D Hucks; R M Priest; Y M Kan; J P Ward
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 3.  New mechanisms of pulmonary arterial hypertension: role of Ca²⁺ signaling.

Authors:  Frank K Kuhr; Kimberly A Smith; Michael Y Song; Irena Levitan; Jason X-J Yuan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-01-13       Impact factor: 4.733

Review 4.  THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes.

Authors:  Stephen P H Alexander; Doriano Fabbro; Eamonn Kelly; Alistair Mathie; John A Peters; Emma L Veale; Jane F Armstrong; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2019-12       Impact factor: 8.739

5.  Chronic hypoxia-induced upregulation of store-operated and receptor-operated Ca2+ channels in pulmonary arterial smooth muscle cells: a novel mechanism of hypoxic pulmonary hypertension.

Authors:  Mo-Jun Lin; George P H Leung; Wei-Min Zhang; Xiao-Ru Yang; Kay-Pong Yip; Chung-Ming Tse; James S K Sham
Journal:  Circ Res       Date:  2004-07-15       Impact factor: 17.367

6.  [Effects of tetramethylpyrazine on angiotensin II -induced proliferation and type I collagen synthesis of rat cardiac fibroblasts].

Authors:  Dong-mei Zhang; Ying Qin; Xi-ying Lu; Ai-ming Wu; Ling-qun Zhu; Shuo-ren Wang; Liang-duo Jiang
Journal:  Zhong Xi Yi Jie He Xue Bao       Date:  2009-03

7.  Sildenafil inhibits chronically hypoxic upregulation of canonical transient receptor potential expression in rat pulmonary arterial smooth muscle.

Authors:  Wenju Lu; Pixin Ran; Dandan Zhang; Gongyong Peng; Bing Li; Nanshan Zhong; Jian Wang
Journal:  Am J Physiol Cell Physiol       Date:  2009-11-04       Impact factor: 4.249

8.  The impact and financial burden of pulmonary arterial hypertension on patients and caregivers: results from a national survey.

Authors:  Zhenguo Zhai; Xia Zhou; Shuai Zhang; Wanmu Xie; Jun Wan; Tuguang Kuang; Yuanhua Yang; Huan Huang; Chen Wang
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

Review 9.  Cardiovascular Actions and Therapeutic Potential of Tetramethylpyrazine (Active Component Isolated from Rhizoma Chuanxiong): Roles and Mechanisms.

Authors:  Ming Guo; Yue Liu; Dazhuo Shi
Journal:  Biomed Res Int       Date:  2016-05-23       Impact factor: 3.411

10.  Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study.

Authors:  Kathryn Coyle; Doug Coyle; Julie Blouin; Karen Lee; Mohammed F Jabr; Khai Tran; Lisa Mielniczuk; John Swiston; Mike Innes
Journal:  Pharmacoeconomics       Date:  2016-05       Impact factor: 4.981

View more
  9 in total

1.  Pharmacological Mechanism of Shen Huang Chong Ji for Treating Alzheimer's Disease Based on Network Pharmacology and Experimental Validation.

Authors:  Lei Tang; Jing Liu; Xiaozhuo Xu; Juan Zhao; Xu Han
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-24       Impact factor: 2.650

2.  Tetramethylpyrazine: A promising drug for the treatment of pulmonary hypertension.

Authors:  Yuqin Chen; Wenju Lu; Kai Yang; Xin Duan; Mengxi Li; Xiuqing Chen; Jie Zhang; Meidan Kuang; Shiyun Liu; Xiongting Wu; Guofa Zou; Chunli Liu; Cheng Hong; Wenjun He; Jing Liao; Chi Hou; Zhe Zhang; Qiuyu Zheng; Jiyuan Chen; Nuofu Zhang; Haiyang Tang; Rebecca R Vanderpool; Ankit A Desai; Franz Rischard; Stephen M Black; Joe G N Garcia; Ayako Makino; Jason X-J Yuan; Nanshan Zhong; Jian Wang
Journal:  Br J Pharmacol       Date:  2020-04-27       Impact factor: 8.739

3.  Increasing Yield of 2,3,5,6-Tetramethylpyrazine in Baijiu Through Saccharomyces cerevisiae Metabolic Engineering.

Authors:  Dan-Yao Cui; Ya-Nan Wei; Liang-Cai Lin; Shi-Jia Chen; Peng-Peng Feng; Dong-Guang Xiao; Xue Lin; Cui-Ying Zhang
Journal:  Front Microbiol       Date:  2020-11-26       Impact factor: 5.640

Review 4.  Bioactivities and mechanisms of natural medicines in the management of pulmonary arterial hypertension.

Authors:  Zhijie Yu; Jun Xiao; Xiao Chen; Yi Ruan; Yang Chen; Xiaoyuan Zheng; Qiang Wang
Journal:  Chin Med       Date:  2022-01-15       Impact factor: 5.455

Review 5.  Traditional Herbal Medicine Discovery for the Treatment and Prevention of Pulmonary Arterial Hypertension.

Authors:  Zhifeng Xue; Yixuan Li; Mengen Zhou; Zhidong Liu; Guanwei Fan; Xiaoying Wang; Yan Zhu; Jian Yang
Journal:  Front Pharmacol       Date:  2021-11-09       Impact factor: 5.810

6.  Tetramethylpyrazine Improves Monocrotaline-Induced Pulmonary Hypertension through the ROS/iNOS/PKG-1 Axis.

Authors:  Dong-Peng Yang; Wen-Peng Dong; Yong-Chao Yang; Yuan-Yuan Zeng; Ying Liu; Zhu Dong; Xi-Miao Ma; Yi-Qiu Cao; Yi-Zhou Bai; Bo Yang; Xiao-Wu Wang
Journal:  J Healthc Eng       Date:  2022-03-24       Impact factor: 2.682

7.  Pitavastatin maintains MAPK7 expression and alleviates angiotensin II-induced vascular endothelial cell inflammation and injury.

Authors:  Min Li; Xiaohua Liu
Journal:  Exp Ther Med       Date:  2021-12-13       Impact factor: 2.447

Review 8.  Natural Products Targeting Liver X Receptors or Farnesoid X Receptor.

Authors:  Jianglian She; Tanwei Gu; Xiaoyan Pang; Yonghong Liu; Lan Tang; Xuefeng Zhou
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

Review 9.  Ion channels as convergence points in the pathology of pulmonary arterial hypertension.

Authors:  Thibault R H Jouen-Tachoire; Stephen J Tucker; Paolo Tammaro
Journal:  Biochem Soc Trans       Date:  2021-08-27       Impact factor: 5.407

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.